SYBREV | Syntax Bio Revolution Index
The Syntax Bio Revolution Index comprises up to 50 equally weighted publicly traded US companies that are developing innovative biological products that aim to improve human health and address climate change problems. The Index applies screens for thematic purity of exposure, liquidity and size, and defines business segments including biofuels, food, biomaterials, life science and agriculture.
The Index uses company classification data structured in Syntax's proprietary Functional Information System (FIS), which draws primarily from audited annual reports (e.g., 10-K filings) and secondarily from unaudited documents (e.g., news articles, company websites) to allow granular groupings and comparisons of companies by the characteristics of their various product lines.
Index Facts
| Number of Constituents | 45 |
| Weighting Methodology | Equal |
| Rebalancing Frequency | Quarterly |
| Currency | USD |
| Exchange Symbol/Ticker | SYBREV |
| Index Inception Date | December 16, 2022 |
| Base Index Value | 1000 |
| Total Return Index Value (as of 05/25/2023) | 1035.74 |
Index Performance
| YTD | 1Q23 | 1Y | 3Y | 5Y | 7Y | 10Y | Since 09.20.19 | |
|---|---|---|---|---|---|---|---|---|
| Bio Revolution | 2.37 | 2.37 | -35.01 | 10.55 | - | - | - | 3.19 |
| S&P 500 | 7.50 | 7.50 | -7.73 | 18.60 | 11.19 | 12.42 | 12.24 | 11.98 |
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Bio Revolution | -47.57 | 6.34 | 80.91 | - | - | - | - | - | - | - |
| S&P 500 | -18.11 | 28.71 | 18.40 | 31.49 | -4.38 | 21.83 | 11.96 | 1.38 | 13.69 | 32.39 |
| Vol. | Sharpe Ratio | Track. Err. | Upside Capture | Down. Capture | |
|---|---|---|---|---|---|
| Bio Revolution | 38.0 | 0.25 | 29.14 | 93.7 | 122.5 |
| S&P 500 | 19.2 | 0.91 | - | 100.0 | 100.0 |
| Beta | Dividend Yield | P / E Ratio | |
|---|---|---|---|
| Bio Revolution | 1.30 | 0.25 | NA |
| S&P 500 | 1.00 | 1.70 | 23.0 |
NA denotes negative valuation.
| Company | Weight (%) |
|---|---|
| Danimer Scientific Inc | 3.12 |
| Lanzatech Global Inc | 2.28 |
| Azenta Inc | 2.23 |
| 10X Genomics Inc | 2.21 |
| Regeneron Pharmaceuticals Inc | 2.19 |
| NuVasive Inc | 2.17 |
| BioLife Solutions Inc | 2.17 |
| NVIDIA Corp | 2.17 |
| Corteva Inc | 2.11 |
| PerkinElmer Inc | 2.11 |
Past performance is no guarantee of future results. The inception date of the Syntax Index is 16 December 2022. Charts and graphs are provided for illustrative purposes only.
The Syntax Index is the property of Syntax, LLC, which calculates and maintains the Indices. Syntax, LLC will not be liable for any errors or omissions in calculating the Index. Syntax®, Stratified®, Stratified Indices®, and Stratified-Weight™ are trademarks or registered trademarks Syntax, LLC.
Index performance does not represent actual fund or portfolio performance and such performance does not reflect the actual investment experience of any investor. An investor cannot invest directly in an index. In addition, the results actual investors might have achieved would have differed from those shown because of differences in the timing, amounts of their investments, and fees and expenses associated with an investment in a portfolio invested in accordance with an index. None of the Syntax Indices or the benchmark indices portrayed herein charge management fees or incur brokerage expenses, and no such fees or expenses were deducted from the performance shown; provided, however, that the returns of any investment portfolio invested in accordance with such indices would be net of such fees and expenses. Additionally, none of these indices lend securities, and no revenues from securities lending were added to the performance shown. Performance shown is unaudited and subject to revision. This site may include materials and documents containing forward-looking statements which are based on our expectations and projections as of the date made. Past returns are not necessarily predictive of future returns.
The S&P 500® Index is an unmanaged index considered representative of the US large-cap stock market.
Top holdings and security classifications used in calculating allocation tables are based on ending weight as of 03/31/2023.